<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<html xmlns:n1="urn:hl7-org:v3" xmlns:in="urn:lantana-com:inline-variable-data" xmlns:sdtc="urn:hl7-org:sdtc"><head>
<meta charset="utf-8"><!-- Do NOT edit this HTML directly: it was generated via an XSLT transformation from a CDA Release 2 XML document. --><title>Progress note - [REDACTED]</title><style type="text/css">
body {
  color: #003366;
  background-color: #FFFFFF;
  font-family: Verdana, Tahoma, sans-serif;
  font-size: 14px;
}

a {
  color: #003366;
  background-color: #FFFFFF;
}

h1 {
  font-size: 20px;
  font-weight: bold;
}

h2 {
  font-size: 18px;
  font-weight: bold;
}

h3 {
  font-size: 14px;
  font-weight: bold;
}

h4 {
  font-size: 14px;
  font-weight: bold;
}


table {
  width: 100%;
}

th {
  background-color: #ffd700;
}

td {
  padding: 0.1cm 0.2cm;
  vertical-align: top;
  background-color: #ffffcc;
}

.h1center {
  font-size: 20px;
  font-weight: bold;
  text-align: center;
  width: 80%;
}

.header_table{
  border: 1pt inset #00008b;
}

.td_label{
  font-weight: bold;
  color: white;
}

.content_span{
 font-family: Verdana, Tahoma, sans-serif;
 display: inline;
 white-space: pre-line;
}

.td_header_role_name{
  width: 20%;
  background-color: #3399ff;
}

.td_header_role_value{
  width: 80%;
  background-color: #ccccff;
}

.Bold{
  font-weight: bold;
}

.Italics{
  font-style: italic;
}

.Underline{
  text-decoration:underline;
}

.internal_format
{
	list-style: none;
	list-style-position:outside;
	margin:0;
	padding:0;
	border:0;
	border-collapse: collapse;
}
          </style></head><body>
<h2><a name="toc">Table of Contents</a></h2><ul><li><a href="#id1">REASON FOR VISIT</a></li><li><a href="#id2">Medications</a></li><li><a href="#id3">Problems</a></li><li><a href="#id4">Encounters</a></li><li><a href="#id5">Assessments</a></li><li><a href="#id6">Plan Of Treatment</a></li><li><a href="#id7">Progress Notes</a></li><li><a href="#id8">History and Physical Notes</a></li></ul><hr align="left" color="teal" size="2"/><h3><a name="id1" href="#toc">REASON FOR VISIT</a></h3><div>PFT</div><h3><a name="id2" href="#toc">Medications</a></h3><div><table width="100%" border="1"><thead><tr><th>Medication</th><th>SIG (Take, Route, Frequency, Duration)</th><th>Notes</th><th>Start Date</th><th>End Date</th><th>Status</th></tr></thead><tbody><tr><td ID="medication1">Singulair 10 mg</td><td ID="instruction1">1 tablet daily Orally Once a day</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication2">Incruse Ellipta 62.5 MCG/INH</td><td ID="instruction2">1 puff Inhalation Once a day for 30 days</td><td/><td>[REDACTED]</td><td/><td>Active</td></tr><tr><td ID="medication3">Ventolin HFA 108 (90 Base) MCG/ACT</td><td ID="instruction3">2 puffs as needed Inhalation every 4 hrs for 30 days</td><td/><td>[REDACTED]</td><td/><td>Active</td></tr><tr><td ID="medication4">Levalbuterol HCl 0.63 MG/3ML</td><td ID="instruction4">3 mL as needed Inhalation every 8 hrs for 30 days</td><td/><td>[REDACTED]</td><td/><td>Active</td></tr><tr><td ID="medication5">Trelegy Ellipta 200-62.5-25 MCG/ACT</td><td ID="instruction5">1 puff Inhalation Once a day for 30 days</td><td/><td>[REDACTED]</td><td/><td>Active</td></tr><tr><td ID="medication6">Lisinopril 20 MG</td><td ID="instruction6">TK 1 T PO QD Oral for 90</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication7">Vyvanse 30 MG</td><td ID="instruction7">(Schedule II Drug) TK 1 C PO BID Oral for 30</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication8">Tessalon Pearles 100 MG</td><td ID="instruction8">1 capsule Orally Two times a day prn for cough for 30 days</td><td/><td>[REDACTED]</td><td/><td>Active</td></tr><tr><td ID="medication9">ProAir 108 (90 Base) MCG/ACT</td><td ID="instruction9">2 puffs as needed Inhalation every 4 hrs for 30 days</td><td/><td>[REDACTED]</td><td/><td>Active</td></tr><tr><td ID="medication10">DuoNeb 0.5-2.5 (3) MG/3ML</td><td ID="instruction10">3 ml Inhalation Four times a day for 30 days</td><td/><td>[REDACTED]</td><td/><td>Active</td></tr><tr><td ID="medication11">Flonase 50 MCG/ACT</td><td ID="instruction11">2 sprays each nare Nasally Once a day for 30 day(s)</td><td/><td>[REDACTED]</td><td/><td>Active</td></tr><tr><td ID="medication12">Sildenafil Citrate 50 MG</td><td ID="instruction12">TAKE ONE TABLET BY MOUTH ONE TIME DAILY AS NEEDED Oral for 30</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication13">oxyCODONE-Acetaminophen 10-325 MG</td><td ID="instruction13">(Schedule II Drug) TK 1 T PO  Q 6 H PRN P Oral for 30</td><td/><td/><td/><td>Active</td></tr></tbody></table></div><h3><a name="id3" href="#toc">Problems</a></h3><div><table width="100%" border="1"><thead><tr><th>Problem Type</th><th>SNOMED Code</th><th>ICD Code</th><th>Onset Dates</th><th>Problem Status</th><th>W/U Status</th><th>Risk</th><th>Notes</th></tr></thead><tbody><tr><td>Problem</td><td>313299006</td><td ID="Problem1">Stage 3 severe COPD by GOLD classification (J44.9)</td><td/><td>Active</td><td>confirmed</td><td/><td/></tr></tbody></table></div><h3><a name="id4" href="#toc">Encounters</a></h3><div><table width="100%" border="1"><thead><tr><th>Encounter</th><th>Location</th><th>Date</th><th>Provider</th><th>Diagnosis</th></tr></thead><tbody><tr><td>[REDACTED] DO PA</td><td>[REDACTED]</td><td>[REDACTED]</td><td>[REDACTED]</td><td>DOE (dyspnea on exertion) R06.09 ; Restrictive airway disease J98.4 and Stage 3 severe COPD by GOLD classification J44.9</td></tr></tbody></table></div><h3><a name="id5" href="#toc">Assessments</a></h3><div><table width="100%" border="1"><thead><tr><th>Encounter Date</th><th>Diagnosis (ICD Code)</th><th>Assessment Notes</th><th>Treatment Notes</th><th>Treatment Clinical Notes</th></tr></thead><tbody><tr><td ID="ref1">[REDACTED]</td><td>DOE (dyspnea on exertion) (ICD-10 - R06.09)</td><td/><td/><td/></tr><tr><td ID="ref2">[REDACTED]</td><td>Restrictive airway disease (ICD-10 - J98.4)</td><td/><td/><td/></tr><tr><td ID="ref3">[REDACTED]</td><td>Stage 3 severe COPD by GOLD classification (ICD-10 - J44.9)</td><td/><td/><td/></tr></tbody></table></div><h3><a name="id6" href="#toc">Plan Of Treatment</a></h3><div>No Information</div><h3><a name="id7" href="#toc">Progress Notes</a></h3><div><ul><li><table width="99%" border="0" cellspacing="0" cellpadding="0"><thead><tr><td><content>[REDACTED] <span class="bold">DOB:</span> [REDACTED] ([REDACTED] M) <span class="bold">Acc No.</span> 30505 <span class="bold">DOS:</span> [REDACTED]</content></td></tr></thead><tbody><tr><td><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td align="right" colspan="2"><span class="bold">PULMONARY FUNCTION TEST</span></td></tr><tr><td align="left"><span class="bold">Patient: </span>[REDACTED]<br/><span class="bold">Account Number: </span>30505</td><td align="right"><span class="bold">Provider: </span>[REDACTED], D.O., P.A.</td></tr><tr><td align="left"/></tr><tr><td align="left"><span class="bold">DOB: </span>[REDACTED]<span class="bold">   Age: </span>61 Y<span class="bold">   Sex: </span>Male</td><td align="right"><span class="bold">Date: </span>[REDACTED]</td></tr><tr><td><span class="bold">Phone: </span>[REDACTED]</td></tr><tr><td colspan="2"><span class="bold">Address: </span>[REDACTED][REDACTED]</td></tr><tr><td colspan="2"><span class="bold">Pcp: </span>[REDACTED]</td></tr></tbody></table></li></ul><br/><content><span class="bold">Subjective:</span></content><br/><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Chief Complaints:</span></td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td>   PFT</td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Medical History:</span> </td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Medications:</span> TakingFlonase 50 MCG/ACT Suspension 2 sprays each nare Nasally Once a day oxyCODONE-Acetaminophen 10-325 MG Tablet (Schedule II Drug) TK 1 T PO  Q 6 H PRN P Oral  Sildenafil Citrate 50 MG Tablet TAKE ONE TABLET BY MOUTH ONE TIME DAILY AS NEEDED Oral  Vyvanse 30 MG Capsule (Schedule II Drug) TK 1 C PO BID Oral  Lisinopril 20 MG Tablet TK 1 T PO QD Oral  ProAir 108 (90 Base) MCG/ACT Aerosol Solution 2 puffs as needed Inhalation every 4 hrs Tessalon Pearles 100 MG Capsule 1 capsule Orally Two times a day prn for cough DuoNeb 0.5-2.5 (3) MG/3ML Solution 3 ml Inhalation Four times a day Incruse Ellipta 62.5 MCG/INH Aerosol Powder Breath Activated 1 puff Inhalation Once a day Singulair 10 mg Tablet 1 tablet daily Orally Once a day Levalbuterol HCl 0.63 MG/3ML Nebulization Solution 3 mL as needed Inhalation every 8 hrs Ventolin HFA 108 (90 Base) MCG/ACT Aerosol Solution 2 puffs as needed Inhalation every 4 hrs Trelegy Ellipta 200-62.5-25 MCG/ACT Aerosol Powder Breath Activated 1 puff Inhalation Once a day Taking Flonase 50 MCG/ACT Suspension 2 sprays each nare Nasally Once a day Taking oxyCODONE-Acetaminophen 10-325 MG Tablet (Schedule II Drug) TK 1 T PO  Q 6 H PRN P Oral  Taking Sildenafil Citrate 50 MG Tablet TAKE ONE TABLET BY MOUTH ONE TIME DAILY AS NEEDED Oral  Taking Vyvanse 30 MG Capsule (Schedule II Drug) TK 1 C PO BID Oral  Taking Lisinopril 20 MG Tablet TK 1 T PO QD Oral  Taking ProAir 108 (90 Base) MCG/ACT Aerosol Solution 2 puffs as needed Inhalation every 4 hrs Taking Tessalon Pearles 100 MG Capsule 1 capsule Orally Two times a day prn for cough Taking DuoNeb 0.5-2.5 (3) MG/3ML Solution 3 ml Inhalation Four times a day Taking Incruse Ellipta 62.5 MCG/INH Aerosol Powder Breath Activated 1 puff Inhalation Once a day Taking Singulair 10 mg Tablet 1 tablet daily Orally Once a day Taking Levalbuterol HCl 0.63 MG/3ML Nebulization Solution 3 mL as needed Inhalation every 8 hrs Taking Ventolin HFA 108 (90 Base) MCG/ACT Aerosol Solution 2 puffs as needed Inhalation every 4 hrs Taking Trelegy Ellipta 200-62.5-25 MCG/ACT Aerosol Powder Breath Activated 1 puff Inhalation Once a day </td></tr></tbody></table></li></ul><br/><content><span class="bold">Objective:</span></content><br/><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><content class="bold">Examination: <br/></content>   <span class="Underline">Pulmonary Function Test:</span><br/>      This is a Complete PFT performed for evaluation of pulmonary function and, shortness of breath. The FEV1/FVC ratio , suggested obstructive lung disease. This suggested  , severe evidence of obstructive lung disease. A trial of bronchodialators , demonstrated a response. The maximum voluntary ventilation , abnormal,  which suggests decreased muscle reserve or poor effort. Total lung volumes were performed , This suggested moderate restrictive disease. Hyperinflation was not noted. The DLCO was normal.    <br/></td></tr><tr><td/></tr></tbody></table></li></ul><br/><content><span class="bold">Assessment:</span></content><br/><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Assessment: </span></td></tr><tr><td/></tr><tr><td>1. DOE (dyspnea on exertion) - R06.09 2. Restrictive airway disease - J98.4 3. Stage 3 severe COPD by GOLD classification - J44.9 </td></tr></tbody></table></li></ul><br/><content><span class="bold">Plan:</span></content><br/><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Treatment:</span></td></tr><tr><td><ul><li/></ul></td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Procedure Codes:</span> 94727 PULM FUNCTION TEST BY GAS94729 C02/MEMBANE DIFFUSE CAPACITY94060 Evaluation of Wheezing Office</td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td colspan="2"><content><span class="bold">Images:</span></content></td></tr></tbody></table></li></ul><br/><ul><li><table width="100%" border="0"><tbody><tr><td/></tr><tr><td valign="top"/></tr><tr><td/></tr><tr><td/></tr><tr><td valign="top">Electronically signed by [REDACTED] , DO  on [REDACTED] 01:16 PM EST</td></tr><tr><td valign="top">Sign off status: Completed</td></tr><tr><td/></tr></tbody></table></li></ul><span class="content_span">true</span></td></tr></tbody><tbody><tr><td><br/><ul><li><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td align="left"><span class="bold">Provider:</span> [REDACTED], D.O., P.A.</td><td align="right"><span class="bold">Date: </span>[REDACTED]</td></tr><tr><td/><td align="right"><span class="content_span">Generated for Printing/Faxing/eTransmitting on: [REDACTED] 05:56 PM EDT</span></td></tr></tbody></table></li></ul></td></tr></tbody></table></li></ul></div><h3><a name="id8" href="#toc">History and Physical Notes</a></h3><div><ul><li><p>Examination</p><table width="100%" border="1"><colgroup><col width="20%"/><col width="20%"/><col width="40%"/><col width="20%"/></colgroup><thead><tr><th>Category</th><th>Sub-Category</th><th>Detail</th><th>Notes</th></tr></thead><tbody><tr><td rowspan="9">Pulmonary Function Test</td><td>This is a Complete PFT performed for</td><td colspan="2">evaluation of pulmonary function and, shortness of breath</td></tr><tr><td>The FEV1/FVC ratio</td><td colspan="2">, suggested obstructive lung disease</td></tr><tr><td>The FEV1</td><td colspan="2"/></tr><tr><td>A trial of bronchodialators</td><td colspan="2">, demonstrated a response</td></tr><tr><td>The maximum voluntary ventilation</td><td colspan="2">, abnormal,  which suggests decreased muscle reserve or poor effort</td></tr><tr><td>This suggested </td><td colspan="2">, severe evidence of obstructive lung disease</td></tr><tr><td>Total lung volumes were performed</td><td colspan="2">, This suggested moderate restrictive disease</td></tr><tr><td>The DLCO was</td><td colspan="2">normal</td></tr><tr><td>Hyperinflation</td><td colspan="2">was not noted</td></tr></tbody></table><br/></li></ul></div><br/><br/>
</body></html>